Pharmacy Times
JANUARY 2, 2024
The new understanding of immune cells could not only contribute to the development of lung disease treatments, but treatments for other organ systems as well.
STAT
JANUARY 2, 2024
AUSTIN, Texas — Eleven years ago, local officials promised voters in the most liberal county in Texas that if they supported tens of millions of dollars in new taxes, they’d deliver a win-win scenario: Austin would get a new medical school, and poor people navigating the health care system in a state with the country’s worst uninsured rate would get more health care services.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
JANUARY 2, 2024
On the heels of a major Paxlovid inventory write-off in the United States, many more doses of Pfizer's COVID-fighting antiviral are going to waste overseas. | At the end of November, more than 1.5 million courses of Pfizer’s Paxlovid had expired unused in European countries, analysts at Airfinity said in a new report. The total tally of expired doses in Europe is expected to hit 3.1 million by the end of next month, representing a value of $2.2 billion.
STAT
JANUARY 2, 2024
For all the flack they get, the country’s four biggest pharmacy benefit managers reported a surprisingly tame average profit margin in the first three quarters of 2023: 4.5%, less than a third of their drugmaker peers. But don’t take their numbers as gospel, experts warned. “It’s really easy to move money around inside the books of a vertically integrated organization,” said Karen Van Nuys, a senior fellow at the USC Schaeffer Center for Health Policy and Econo
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
JANUARY 2, 2024
Real-world data can help resolve access barriers by providing a highly detailed view into the barriers that impact specific patient populations.
STAT
JANUARY 2, 2024
The first phone call came some time in late 1996. “Ed, I’d like to introduce myself. My name is Sid Wolfe of Public Citizen,” he said. “And I’ve got something for you.” He started out matter of fact, but spoke very quickly. To be honest, I can’t recall the subject anymore, but I do remember he peppered every sentence with lots of medical terminology.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
JANUARY 2, 2024
The blue muffin challenge. Food sensitivity tests. Microbiome test kits. Self-help gastrointestinal health is all the rage. Rightly so: One in four Americans is affected by digestive disorders. And we’re all eating worse, sleeping less, and experiencing more stress , leaving our guts feeling twisted.
Pharmacy Times
JANUARY 2, 2024
Patients who receive stimulation at different parts of the brain may reap benefits.
Drug Topics
JANUARY 2, 2024
Higher concentrations of omega-3 fatty acids were associated with the ability to exchange carbon dioxide more efficiently and longer transplant-free survival.
STAT
JANUARY 2, 2024
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Power, politics, and care for the poor in Texas Local officials in Austin, Texas promised twelve years ago that if voters approved millions of dollars in new property taxes, it would be a win-win.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Drug Topics
JANUARY 2, 2024
2023 was a year packed with advancements in the vaccine, biosimilar, and therapeutic spaces. Explore the approvals that emerged in 2023 from these advancements in our slideshow series outlining the impact of each on the general health care landscape.
STAT
JANUARY 2, 2024
WASHINGTON — The Biden administration seemed to be giving pharmacies a win when they forced pharmacy benefit managers to be more up-front about the behind-the-scenes fees they charge. But now pharmacies are afraid the transition to the new system on Jan. 1 will lead to a cash flow crunch. In the past, PBMs could charge pharmacies performance-based fees long after the fact, and the total amount of the fees has grown in recent years.
pharmaphorum
JANUARY 2, 2024
Verona Pharma has agreed a new $400 million debt facility with Oxford Finance and Hercules Capital designed to help the company navigate the possible approval and launch of ensifentrine, its therapy for chronic obstructive pulmonary disease (COPD). The Anglo-US company has already tapped $50 million of the funding and can take another $100 million if an ongoing review of ensifentrine by the US FDA results in regulatory approval.
Fierce Healthcare
JANUARY 2, 2024
Yet another notable payer-provider contract negotiation is going public. | In a statement, the health system said that the insurance giant underpays for its services compared to other providers in the region.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
JANUARY 2, 2024
True patient centricity treats the whole patient and places an emphasis on broader patient engagement and satisfaction.
STAT
JANUARY 2, 2024
AUSTIN, Texas — The partnership between one of the nation’s largest Catholic health systems and a local government agency focused on caring for poor patients was supposed to be mutually beneficial for everyone involved. But it didn’t quite turn out that way. The alliance in theory meant that Travis County, home to the growing metro area of Austin, could provide more care to low-income patients cheaper than other big cities in the state.
Fierce Pharma
JANUARY 2, 2024
AstraZeneca and Sanofi have scored first in | AstraZeneca and Sanofi have scored first in China with an approval for their respiratory syncytial virus (RSV) immunization Beyfortus for infants, with the companies expecting the shot to be available there for the 2024-25 season. Beyfortus is the only immunization approved for babies entering their first RSV season to protect them against lower respiratory tract infection.
Pharmacy Times
JANUARY 2, 2024
At a time when pharmacist burnout and turnover is higher than ever before, talent retention is increasingly a strategic imperative for hospitals.
STAT
JANUARY 2, 2024
Is it too early to say that the health tech boom feels like a million years ago? In 2020 and 2021, the jolt of pandemic and favorable economic conditions created an explosion of adoption and investment for companies that hoped to transform some corner of the stodgy health care system with technology. Those roaring days feel like a distant memory. Many of those would-be disrupters are now struggling through a much different environment.
pharmaphorum
JANUARY 2, 2024
Novo Nordisk is planning to open an AI research facility in London, UK, as part of a drive to place the technology at the heart of its drug discovery operations
STAT
JANUARY 2, 2024
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: In December, Vertex Pharmaceuticals announced results from a mid-stage clinical trial showing its experimental, non-opioid drug reduced pain in people with diabetes who have chronic pain. This quarter, the company will read out results from Phase 3 studies of the same pain drug, called VX-548, in people with acute pain following surgery.
The Checkup by Singlecare
JANUARY 2, 2024
From stress and caffeine withdrawal to genetic predisposition, there are loads of reasons why you might get a headache on a regular basis. But one often overlooked, but common cause is dehydration, even mild dehydration can cause headache pain. Here, learn how to determine if dehydration is contributing to your pain, plus steps you can take to manage symptoms and prevent them from recurring in the future.
STAT
JANUARY 2, 2024
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in your inbox every Monday. UnitedHealth had rules to deny rehab care for certain MA members Throughout 2023, my colleague Casey Ross and I explored how UnitedHealth Group and its care management subsidiary, NaviHealth, have used an algorithm to cut off rehab care for people enrolled in Medicare Advantage.
European Pharmaceutical Review
JANUARY 2, 2024
A paper published in the European Journal of Pharmaceutics and Biopharmaceutics has reviewed the current application status of Quality by Design (QbD) within the framework of the ICH guidelines (ICH Q8(R2) – Q14 and ICH Q2(R2)). Over the past several years, the pharmaceutical industry has faced challenges regarding quality assurance in drug development, the author asserted.
STAT
JANUARY 2, 2024
CAMBRIDGE — Vietnamese-born entrepreneur Jean Pham is “graduating” from LabCentral, a biotech launchpad on the edge of Kendall Square, after enjoying free lab space for the past year. Pham and a pair of employees at her three-year-old company, Cellens, shared high-tech research instruments with scores of other scientists, under a LabCentral program aiding startups owned by women and people of color.
Drug Topics
JANUARY 2, 2024
Study authors theorized that the reduced effect could be due to disease-related or immunosuppressive treatment factors.
PharmExec
JANUARY 2, 2024
Companies must address myriad challenges to improve upon issues such as data quality and transparency, process efficiency, and artificial intelligence/machine learning preparedness.
Fierce Healthcare
JANUARY 2, 2024
Healthcare mergers and acquisitions are in no short supply as providers, health tech companies, retailers and other industry players look to expand their businesses and gain a competitive edge. | Start-and-stop merger plans among major payers, a Providence spinout's nine-figure sale and more merger and acquisition news from the month of December.
Pharmaceutical Commerce
JANUARY 2, 2024
Agreement includes novel cell therapy for hematology that has the opportunity to bring a potential best-in-class treatment to patients with blood cancers.
Drug Store News
JANUARY 2, 2024
Acosta Group shared its five retail predictions for 2024, which include changes in technology, marketing and consumer trends.
pharmaphorum
JANUARY 2, 2024
Novartis has doubled down on its gene therapy collaboration with Voyager Therapeutics, licensing candidates for Huntington's disease and SMA
Pharmacy Times
JANUARY 2, 2024
Health coaches supporting remote pharmacist services can improve diabetes disparities.
pharmaphorum
JANUARY 2, 2024
Astellas has licensed up to four macrophage enhancer drugs with potential as cancer immunotherapies from Elpiscience in a $1.
Drug Store News
JANUARY 2, 2024
Caroline Callaway, president and founder of Bolt PR, shares why the consumer product sector needs more women in C-Suite leadership roles.
Expert insights. Personalized for you.
148 
Let's personalize your content